Novo Nordisk(US:NVO) Jing Ji Guan Cha Wang·2025-09-10 12:53Core Viewpoint - Novo Nordisk announced a layoff of approximately 9,000 employees, aiming to save 8 billion Danish kroner (approximately 8.94 billion RMB) annually by the end of 2026, as part of a transformation plan due to recent growth slowdown [2][4] Group 1: Layoff and Financial Impact - The layoff represents about 11% of Novo Nordisk's global workforce of 78,400 employees, with over half of the cuts expected to come from the headquarters in Denmark [2][4] - The company has revised its 2025 operating profit growth forecast down to 4%-10%, from a previous estimate of 10%-16% [2] - The transformation plan is expected to incur a one-time restructuring cost of 8 billion Danish kroner, which will negatively impact the operating profit growth forecast by approximately 6 percentage points [4] Group 2: Market Context and Strategic Shift - Novo Nordisk's recent growth has slowed, particularly in key markets like the U.S. and China, where sales of its diabetes drug, semaglutide, saw an 11% decline in the first half of the year [3] - The company aims to simplify its organizational structure and enhance decision-making speed to better allocate resources towards growth opportunities in diabetes and obesity treatment [2][4] - The new CEO, Dumitru, emphasized the need for a performance-oriented culture and effective resource deployment in response to increasing competition in the obesity market [4]